Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
AuthorsJayson, Gordon C
Julyan, Peter J
Ranson, Malcolm R
Smith, Nigel K
Hastings, David L
Lawrance, Jeremy A L
Ward, Timothy H
McGown, Alan T
Lehmann, Frederic F
AffiliationCancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. Gordon.Jayson@christie-tr.nwest.nhs.uk
MetadataShow full item record
AbstractBACKGROUND: Vascular endothelial growth factor (VEGF) is a potent angiogenic cytokine, and various inhibitory agents, including specific antibodies, have been developed to block VEGF-stimulated angiogenesis. We developed HuMV833, a humanized version of a mouse monoclonal anti-VEGF antibody (MV833) that has antitumor activity against a number of human tumor xenografts, and investigated the distribution and biologic effects of HuMV833 in patients in a phase I trial. METHODS: Twenty patients with progressive solid tumors were treated with various doses of HuMV833 (0.3, 1, 3, or 10 mg/kg). Positron emission tomography with (124)I-HuMV833 was used to measure the antibody distribution in and clearance from tissues. Magnetic resonance imaging was used to measure the vascular permeability surface area product with a first-pass pharmacokinetic model (k(fp)) to determine tumor vascular permeability. RESULTS: The antibody was generally well tolerated, although the incremental dose, phase I study design, and pharmacodynamic endpoints could not identify the optimum biologically active dose. Antibody distribution and clearance were markedly heterogeneous between and within patients and between and within individual tumors. HuMV833 distribution to normal tissues also varied among patients, but the antibody was cleared from these tissues in a homogeneous fashion. Permeability was strongly heterogeneous between and within patients and between and within individual tumors. All tumors showed a reduction in k(fp) 48 hours after the first treatment (median = 44%; range = 4%-91%). CONCLUSIONS: Because of the heterogeneity in tumor biology with respect to antibody uptake and clearance, we suggest that either intrapatient dose escalation approaches or larger, more precisely defined patient cohorts would be preferable to conventional strategies in the design of phase I studies with antiangiogenic compounds like HuMV833.
CitationMolecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. 2002, 94 (19):1484-93 J. Natl. Cancer Inst.
JournalJournal of the National Cancer Institute
- Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
- Authors: Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB
- Issue date: 1999 Jan
- Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
- Authors: Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H
- Issue date: 1995 Nov 15
- Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor.
- Authors: Asano M, Yukita A, Suzuki H
- Issue date: 1999 Jan
- An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo.
- Authors: Asano M, Yukita A, Matsumoto T, Hanatani M, Suzuki H
- Issue date: 1998 Apr
- Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
- Authors: Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D
- Issue date: 2001 Feb 1